sameAs
Structure-Based Mutational Analysis of the Hepatitis C Virus NS3 HelicasePlasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinomaInterferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.Laserthermia for the treatment of small hepatocellular carcinoma: a preliminary study.Low-power laserthermia for the treatment of small hepatocellular carcinoma.Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.Milder clinical manifestation of scrub typhus in Kinmen, Taiwan.The conserved serine 177 in the delta antigen of hepatitis delta virus is one putative phosphorylation site and is required for efficient viral RNA replicationRapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome dataFunctional measurement of hepatitis C virus core-specific CD8(+) T-cell responses in the livers or peripheral blood of patients by using autologous peripheral blood mononuclear cells as targets or stimulators.Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma modelIncreased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infectionCancer prevention in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathwayRecent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma.Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection.Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma.Global control of hepatitis B virus infection.ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancersAge-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiotaPrevention of hepatitis B.Depletion of β-catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development.Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular CarcinomaHepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibitionChanging disease burden of hepatocellular carcinoma in the Far East and Southeast Asia.Therapeutic implications of hepatitis B virus genotypes.Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT.Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution.Induction of liver alpha-1 acid glycoprotein gene expression involves both positive and negative transcription factorsPurification and characterization of nucleolin and its identification as a transcription repressor.Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy.Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice.Dual chronic hepatitis B virus and hepatitis C virus infection.Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model.Toward elimination and eradication of hepatitis B.Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects.Hepatitis B virus infection, its sequelae, and prevention by vaccination.
P50
Q27469958-149E17DA-049E-43F0-AC88-E2D9844BF40CQ28237242-F8FB7BB8-E741-40FB-9771-2D67157C4471Q30579693-1E291694-4DB6-4A1A-BCCE-E2B401E824CDQ30663552-3C9E94B3-61F5-4AA7-B4DF-0A673D5B1CF1Q33241322-A8A77B8B-3EE2-42C1-B516-DBF87E58AE23Q33365961-D06D63AF-ED5D-4CCA-8FF5-6B9A89827BA5Q33406716-82285E7E-A42F-4A79-A4A8-04E27E3E253FQ33845329-3EE033AD-7272-4424-867E-DB9D73906E90Q33951424-732DFD47-2556-47F6-A028-5C65F301206AQ33973907-A5DD2485-0AAC-40AA-9293-00C72C54F2BAQ34093354-58081C68-E2D5-4748-97F4-6828B2DE4256Q34130446-01FFCB4E-1AB0-4510-A419-F8926BCC4F07Q34381609-07870F92-B1E2-4D46-804A-037D0ED243E1Q34409751-9D5C7454-8E37-4BCF-95F4-A3ECE90511BFQ34483036-F645E5D6-9825-4F1C-94D4-0C105ADCD609Q34598267-7170AA5A-29DA-47C3-B269-BA58EBFD0ABEQ34603312-4F17D231-D64B-45B3-9C72-F8882A7FFD80Q34749752-231722D1-26D3-4611-A80E-1180F0539B20Q35079974-6B771747-BDCD-4BAD-81AB-FB27F18312F8Q35129064-0A77A52F-8E6E-4A77-AFAF-3A9C60E3155BQ35164249-30709E2E-33F8-4213-8B67-84EE4534212BQ35546735-5A39C12D-4292-4659-8D93-B0E8629AD937Q35595548-295DA244-C92D-4533-967F-670D93E69D1CQ35612596-D98DF4C5-4E22-4122-9426-AF8A31D92996Q35740334-42E70B3D-A23F-43A4-B429-D26799698BF1Q36184218-EACC13C8-BF9C-4E03-A267-D47740F6EA7AQ36338675-F60F6FC0-99BD-4B25-9D1E-FD133F05F8D5Q36532437-CB12B807-6BA8-4411-80D0-0FC4E52A8F2CQ36602760-A1B2D6FB-E109-45ED-9474-73267ADC7B2FQ36659529-B2FA2E95-61BB-40D8-98EF-70C3D755A173Q36665526-7CC17810-C49D-481D-BDA2-543B315DD302Q36841560-658784F0-0D54-47DA-A57F-6144398AB603Q37208941-A8944C4E-97CE-40D9-9373-DFDA5FA7171FQ37369324-7619CFC1-F3B0-431F-BA57-D1C1ADCEBC9EQ37466211-2C9431FD-B4EE-4544-ABA1-2D1066CE5513Q37534152-B31C13B2-EAE1-4924-8791-F78FEABDE461Q37565083-1A36C819-6F34-49CB-91BE-C1FC6B1A3C90Q37688282-3F788EA3-281F-451B-8EA8-899E0701B562Q37804991-D38561C8-3CBD-43BD-9065-A6BFF82767D8Q37831695-59159B1F-93BD-4A43-AC49-8E143F143698
P50
description
Taiwanese scientist and physician
@en
apotheker uit Taiwan
@nl
name
Ding-Shinn Chen
@en
Ding-Shinn Chen
@es
Ding-Shinn Chen
@nl
Ding-shinn Chen
@sl
陳定信
@zh
type
label
Ding-Shinn Chen
@en
Ding-Shinn Chen
@es
Ding-Shinn Chen
@nl
Ding-shinn Chen
@sl
陳定信
@zh
altLabel
Chen Ding-Shinn
@en
Ding-shinn Chen
@en
陳定信
@en
prefLabel
Ding-Shinn Chen
@en
Ding-Shinn Chen
@es
Ding-Shinn Chen
@nl
Ding-shinn Chen
@sl
陳定信
@zh
P244
P106
P1153
36066251200
P21
P214
P244
n2016188599
P2456
P27
P31
P39
P496
0000-0001-7791-6154
P5380
P569
1943-07-06T00:00:00Z
P734
P7859
lccn-n2015190332
lccn-n2016188599